Following adults with asthma over several years, including biologic treatment
Tracks how asthma types change over time in adults with or without nasal polyps.
Plain-language title generated from the registry record
Registry title: Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry
Key facts
- Where
- A Coruña, Badalona, Barcelona, Madrid, Pamplona, and Santiago de Compostela, SpainSee the 8 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06163807, who can take part
Where in Spain
- Hospital Del FerrolA Coruña, SpainTaking people
- Hospital Universitario Germans TriasBadalona, SpainTaking people
- Hospital ClinicBarcelona, SpainTaking people
- Hospital Universitari Vall de HebronBarcelona, SpainTaking people
- Hospital Universitario Sant PauBarcelona, SpainTaking people
- Hospital Universitario La PazMadrid, SpainTaking people
- Hospital Universitario de NavarraPamplona, SpainTaking people
- Hospital Universitario Santiago de CompostelaSantiago de Compostela, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Trial code
- NCT06163807
- Record updated
- 30 March 2026
- Original description
Primary objectiveRead full original descriptionShow less
Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry
Primary objective
- To study the stability of different phenotypes and endotypes of asthma at 3, 5, and 7 years of follow-up and - in MEGA COHORT and in patients on biologic treatment
Secondary objective(s)
* To study biomarkers variation post-treatment in patients with and without Nasal Polyposis * To demonstrate the existence of different subtypes of eosinophils that may be phenotypically and functionally heterogeneous * To increase the number of patients in the cohort on biologic treatment to reach at least 900 (400 over the current cohort).
Inclusion: For the general asthma cohort (MEGA):; Age from 18 to 80 y.o. with asthma with and without nasal polyposis based on GINA guidelines (compatible clinical symptoms+reversibility of at least 12% and 200 mL in FEV1 after the administration of 200-400 μg albuterol/salbutamol or positive methacholine test) of several severities attended at participant centres; Already in follow-up in MEGA cohort; To participate in the study; Signed informed consent; Patients from 18 to 80 y.o. with uncontrolled asthma with and without nasal polyposis that fulfil criteria to be treated with biological drugs (Existing treatment with medium-to-high-dose ICS (≥ 250 μg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 μg/day of fluticasone propionate or equivalent) in combination with a second controller (e.g., LABA, LTRA) for at least 3 months+ airflow limitation- FEV1 <80%/FEV1/FVC <70+ACQ-5 score ≥ 1.5/ ACT < 19 at inclusion and/or have experience any of the following events on the last year: treatment with systemic steroids/ hospitalization or emergency medical care visit for worsening asthma; When planning dupilumab, mepolizumab, benralizumab or reslizumab, biomarker levels, and exacerbation in the previous year will be considered according to the Spanish Ministry of Health recommendations for reimbursement of any biological drug in severe asthma. In the case of Omalizumab allergic asthma and IgE > 75 and < 1500 UI; Patients already in follow-up in the cohort of patients treated with biologics; Willing to participate in the study; Sign informed consent.
Exclusion: Exclusion criteria for asthma patients treated with biologics; Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function; Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders; Patients participating in other clinical trials; Patients without the capacity to understand the aim of the study; Exclusion criteria for MEGA COHORT; Diagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung function; Comorbid disease that might interfere with the evaluation, e.g. psychiatric disorders; Patients participating in other clinical trials; Patients without the capacity to understand the aim of the study.